Anurag Relan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5039188/publications.pdf

Version: 2024-02-01

36	963	430754	434063
papers	citations	18 h-index	31 g-index

36	36	36	517
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry. World Allergy Organization Journal, 2021, 14, 100535.	1.6	3
2	Population pharmacokinetics of recombinant human C1 esterase inhibitor in children with hereditary angioedema. Annals of Allergy, Asthma and Immunology, 2021, 126, 707-712.	0.5	1
3	Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 203-210.	0.5	2
4	Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2938-2940.	2.0	14
5	Cost-effectiveness model for on-demand treatment of hereditary angioedema (HAE) attacks. Journal of Drug Assessment, 2019, 8, 22-22.	1.1	0
6	Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. Pediatric Allergy and Immunology, 2019, 30, 562-568.	1.1	18
7	C1 esterase inhibitor concentrates and attenuated androgens â€“ Authors' reply. Lancet, The, 2018, 391, 1356.	6.3	1
8	Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks. Allergy and Asthma Proceedings, 2018, 39, 359-364.	1.0	9
9	Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1091-1097.	2.0	9
10	Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. Annals of Allergy, Asthma and Immunology, 2017, 118, 452-455.	0.5	12
11	Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet, The, 2017, 390, 1595-1602.	6.3	55
12	Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement. Allergy and Asthma Proceedings, 2017, 38, 462-466.	1.0	13
13	Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks. Allergy and Asthma Proceedings, 2017, 38, 456-461.	1.0	8
14	Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation process. Journal of Allergy and Clinical Immunology, 2016, 138, 359-366.	1.5	63
15	Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milk. Journal of Allergy and Clinical Immunology, 2016, 138, 476-481.e1.	1.5	3
16	C1 Inhibitor Limits Organ Injury and Prolongs Survival in Swine Subjected to Battlefield Simulated Injury. Shock, 2016, 46, 177-188.	1.0	16
17	Hereditary Angioedema Attacks: Local Swelling at Multiple Sites. Clinical Reviews in Allergy and Immunology, 2016, 50, 34-40.	2.9	22
18	Elevated <scp>D</scp>â€dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 506-513.	2.7	62

#	Article	IF	Citations
19	Recombinant Human-C1 Inhibitor Is Effective and Safe for Repeat Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 417-423.	2.0	32
20	Sustained Response Following Acute Treatment Of Hereditary Angioedema Attacks With Recombinant Human C1 Esterase Inhibitor. Journal of Allergy and Clinical Immunology, 2014, 133, AB37.	1.5	1
21	C-reactive protein levels in hereditary angioedema. Clinical and Experimental Immunology, 2014, 177, 280-286.	1.1	20
22	Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Annals of Allergy, Asthma and Immunology, 2014, 112, 163-169.e1.	0.5	70
23	Recombinant Human C1 Inhibitor Treatment Does Not Affect D-Dimer Levels and Is Not Associated With Thromboembolic Events In HAE Patients. Journal of Allergy and Clinical Immunology, 2014, 133, AB36.	1.5	0
24	Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Annals of Allergy, Asthma and Immunology, 2013, 110, 295-299.	0.5	51
25	Population pharmacokinetics of recombinant human <scp>C1</scp> inhibitor in patients with hereditary angioedema. British Journal of Clinical Pharmacology, 2013, 76, 897-907.	1.1	29
26	Immunosafety of Recombinant Human C1-Inhibitor in Hereditary Angioedema: Evaluation of IgE Antibodies. Clinical Drug Investigation, 2013, 33, 275-281.	1.1	14
27	Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 118-124.	2.7	38
28	84â€ƒImmuno-Safety of Recombinant Human C1 Inhibitor in Patients With Hereditary Angioedema. World Allergy Organization Journal, 2012, 5, S28.	1.6	0
29	Content Validity of Visual Analog Scales to Assess Symptom Severity of Acute Angioedema Attacks in Adults with Hereditary Angioedema. Patient, 2012, 5, 113-126.	1.1	18
30	Recombinant C1-Inhibitor. BioDrugs, 2012, 26, 43-52.	2.2	28
31	Clinical Impact of Peripheral Attacks in Hereditary Angioedema Patients. American Journal of Medicine, 2012, 125, 937.e17-937.e24.	0.6	22
32	Immunogenicity Assessment of Recombinant Human C1-Inhibitor. BioDrugs, 2012, 26, 303-313.	2.2	19
33	Target levels of functional C1â€inhibitor in hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 123-130.	2.7	51
34	Efficacy and safety of recombinant human C1â€inhibitor for the treatment of attacks of hereditary angioedema: European openâ€label extension study. Clinical and Experimental Allergy, 2012, 42, 929-935.	1.4	50
35	Immunogenicity Assessment of Recombinant Human C1-Inhibitor. BioDrugs, 2012, 26, 303-313.	2.2	6
36	Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology, 2010, 126, 821-827.e14.	1.5	203